复星医药(02196.HK)治疗肌萎缩侧索硬化药物获美国同意开展临床试验

阿斯达克财经
11 Feb

复星医药(02196.HK) (600196.SH) 公布,其控股子公司复宏汉霖近日收到美国食品药品监督管理局(FDA)关于同意HLX99开展临床试验的批准。复宏汉霖拟于条件具备后在美国开展HLX99的I期临床试验。
HLX99为集团自主研发的创新型小分子偶联化学药物,拟用于治疗肌萎缩侧索硬化(ALS)。

截至去年12月,集团现阶段针对HLX99累计研发投入约为1,300万元人民币(未经审计)。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-10 16:25。) (A股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10